Clinical Outcomes and Immune-Related Adverse Events in Metastatic Non-Squamous NSCLC Treated with First-Line Pembrolizumab-Chemotherapy: A Real-World Study from Serbia.

Curr Oncol · 2026 · PMC13205886 · PMID 42187584

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

reported that the occurrence of irAEs was associated with overall clinical benefit; notably, skin reactions tended to be associated with improved outcomes, although this did not reach statistical significance in their smaller cohort.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.